Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PTC Therapeutics's revenue for the
three
months ended in Jun. 2026 was €312.9 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €869.1 Mil.
PTC Therapeutics's Revenue per Share for the
three
months ended in Jun. 2026 was €3.40.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €9.84.
Warning Sign:
PTC Therapeutics Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of PTC Therapeutics was -46.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 26.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 23.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 25.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, PTC Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 83.70% per year. The lowest was -42.40% per year. And the median was 17.20% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
PTC Therapeutics Revenue Related Terms
PTC Therapeutics Revenue Historical Data
* Premium members only.
The historical data trend for PTC Therapeutics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PTC Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €869.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (FRA:BH3) has a Revenue of €869.1 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Revenue too high?
PTC Therapeutics' current Revenue is €869.1 Mil. Overall, PTC Therapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Revenue compare to XENE and CGON?
PTC Therapeutics' Revenue of €869.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Revenue is €869.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Revenue of €869.1 Mil. The stock's GF Value™ is €31.98, compared to a current price of €58.54 — trading 83.1% above its estimated fair value. The current Revenue is €869.1 Mil. PTC Therapeutics' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Revenue is €869.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?
Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued.
The current stock price of €58.54 is trading 83.1% above its estimated GF Value™ of €31.98.
Key valuation signals for FRA:BH3:
Revenue: €869.1 Mil
GF Value™: €31.98 vs. price of €58.54 (83.1% above fair value)
No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
53GF Score
Get the complete analysis for FRA:BH3
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BH3 has been successfully added to your 
